These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27878989)

  • 21. Discovery of 3,5-Dimethyl-4-Sulfonyl-1
    Zhu PJ; Yu ZZ; Lv YF; Zhao JL; Tong YY; You QD; Jiang ZY
    J Med Chem; 2021 Aug; 64(15):11330-11353. PubMed ID: 34342996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
    Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
    PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and development of thiazolidine-2,4-dione derivatives as Bcl-2/Mcl-1 dual inhibitors.
    Long J; Chen H; Yan Z; Zhou L; Deng R; Wang J; Tang Z; Wan Y
    Bioorg Chem; 2024 Oct; 151():107687. PubMed ID: 39096559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1
    Deng H; Zhang J; Liu L; Zhang H; Han Y; Wu L; Jing Y; Huang M; Zhao L
    J Med Chem; 2024 Aug; 67(16):13925-13958. PubMed ID: 39121336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural revision of the Mcl-1 inhibitor MIM1: synthesis and biological studies on ovarian cancer cells with evaluation of designed analogues.
    Paysant H; Hedir S; Justaud F; Weiswald LB; El Dine AN; Soulieman A; Hachem A; Elie N; Brotin E; Denoyelle C; Bignon J; Roussi F; Jouanne M; Tasseau O; Roisnel T; Voisin-Chiret AS; Grée R; Levoin N; Poulain L
    Org Biomol Chem; 2021 Oct; 19(41):8968-8987. PubMed ID: 34596646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.
    Zhu PJ; Yu ZZ; You QD; Jiang ZY
    Drug Discov Today; 2020 Oct; 25(10):1873-1882. PubMed ID: 32771436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
    Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
    Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
    Wang B; Ni Z; Dai X; Qin L; Li X; Xu L; Lian J; He F
    Mol Cancer; 2014 Apr; 13():98. PubMed ID: 24779770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
    Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML
    Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-Based Optimization of 3-Phenyl-
    Li Y; Fan W; Gong Q; Tian J; Zhou M; Li Q; Uwituze LB; Zhang Z; Hong R; Wang R
    J Med Chem; 2021 Jul; 64(14):10260-10285. PubMed ID: 34228434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MCL-1 inhibitors - where are we now (2019)?
    Fletcher S
    Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
    [No Abstract]   [Full Text] [Related]  

  • 33. Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis.
    Varadarajan S; Butterworth M; Wei J; Pellecchia M; Dinsdale D; Cohen GM
    Neoplasia; 2013 May; 15(5):568-78. PubMed ID: 23633928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity.
    Szlávik Z; Ondi L; Csékei M; Paczal A; Szabó ZB; Radics G; Murray J; Davidson J; Chen I; Davis B; Hubbard RE; Pedder C; Dokurno P; Surgenor A; Smith J; Robertson A; LeToumelin-Braizat G; Cauquil N; Zarka M; Demarles D; Perron-Sierra F; Claperon A; Colland F; Geneste O; Kotschy A
    J Med Chem; 2019 Aug; 62(15):6913-6924. PubMed ID: 31339316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent.
    Lu X; Liu YC; Orvig C; Liang H; Chen ZF
    J Med Chem; 2020 Sep; 63(17):9154-9167. PubMed ID: 32794745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
    Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
    Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.
    Abulwerdi FA; Liao C; Mady AS; Gavin J; Shen C; Cierpicki T; Stuckey JA; Showalter HD; Nikolovska-Coleska Z
    J Med Chem; 2014 May; 57(10):4111-33. PubMed ID: 24749893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
    Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
    Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.